Global Autoimmune Disorder Drugs Market 2021

January 2022 | 19 pages | ID: G0E1E3E681F5EN
StrategyHelix Inc

Abstracts

According to NIH, autoimmune disorders are conditions in which the body's immune system mistakenly attacks and destroys healthy tissues of the body by perceiving them as foreign bodies. The majority of autoimmune disorders cause inflammation of affected parts of the body. The most commonly occurring autoimmune disorder include psoriasis, systemic lupus erythematosus, and rheumatoid arthritis, among others. According to a report by StrategyHelix, the global autoimmune disorder drugs market is set to increase by US$ 40,299 million during 2021-2027, growing at a CAGR of 9.8% during the forecast period. Growth in the geriatric population, increasing prevalence of autoimmune disorders, the rise in technological advancements for the diagnosis of autoimmune diseases are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for autoimmune disorder drugs. The global autoimmune disorder drugs market is segmented on the basis of type, indication, and region. On the basis of type, the global autoimmune disorder drugs market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressant drugs. The NSAIDs segment held the largest revenue share in 2020. By indication, the global autoimmune disorder drugs market has been segmented into rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, others. Among these, the rheumatoid arthritis segment was accounted for the highest revenue generator in 2020. Geographically, the global autoimmune disorder drugs market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global autoimmune disorder drugs market is highly competitive. Key companies profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Vertex Pharmaceuticals Inc.

Report Scope
Type: nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressant drugs
Indication: rheumatoid arthritis, systemic lupus erythematosus, psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global autoimmune disorder drugs market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. AUTOIMMUNE DISORDER DRUGS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY TYPE

Nonsteroidal anti-inflammatory drugs (NSAIDs)
Immunosuppressant drugs

PART 4. MARKET BREAKDOWN BY INDICATION

Rheumatoid arthritis
Systemic lupus erythematosus
Psoriasis/psoriatic arthritis
Multiple sclerosis
Inflammatory bowel disease
Type 1 diabetes
Others

PART 5. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 6. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol Myers Squibb (BMS)
Johnson & Johnson
Mylan N.V.
Novartis AG
Pfizer Inc.
Roche Holding AG
Vertex Pharmaceuticals, Inc.
About StrategyHelix
Disclaimer